Overview

Randomized Trial Sorafenib-Pravastatin Versus Sorafenib Alone for the Palliative Treatment of Child-Pugh A Hepatocellular Carcinoma

Status:
Completed

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

Principal objective: to evaluate the effect of the combination pravastatin - sorafenib versus sorafenib alone on overall survival in patients with hepatocellular carcinoma developing on Child-Pugh A cirrhosis who are unsuitable for curative treatment. Secondary objectives: evaluate the effect of this treatment on progression-free survival, the time to progression, the time to treatment failure and quality of life (QLQ-C30 et FACT HEP)

Phase:

Phase 3

Details

Lead Sponsor:

Centre Hospitalier Universitaire Dijon

Treatments:

Niacinamide
Pravastatin
Sorafenib